<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888756</url>
  </required_header>
  <id_info>
    <org_study_id>iHIVARNA phase II</org_study_id>
    <secondary_id>2016-002724-83</secondary_id>
    <nct_id>NCT02888756</nct_id>
  </id_info>
  <brief_title>iHIVARNA Clinical Trial in HIV Infected Individuals</brief_title>
  <acronym>iHIVARNA-01</acronym>
  <official_title>A Phase IIa Randomized, Placebo Controlled, Double Blinded Study to Evaluate the Safety and Immunogenicity of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rob Gruters</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IrsiCaixa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synapse bv</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asphalion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>eTheRNA immunotherapies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CR2O</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      iHIVARNA-01 is a novel therapeutic vaccine for the treatment of HIV-1-infected patients based
      on in vivo modification of DCs. It consists of HIVACAT-TriMix: mRNA encoding a mixture of APC
      activation molecules (CD40L, a constitutively active variant of TLR4 and CD70) and the HIV
      target antigens contained in HIVACAT to be administered through the intranodal route.
      iHIVARNA-01 aims to achieve the 'functional cure' of HIV infection, i.e. controlling viral
      replication in the absence of anti-retroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To evaluate the safety and immunogenicity of iHIVARNA-01 as a new therapeutic
      vaccine in HIV infected patients.

      Study design and duration: Phase IIa, multicentre double-blind placebo controlled
      intervention study. Each patient will be followed for 30 weeks. The study duration will be 38
      weeks from inclusion of the first patient.

      Sites: Erasmus MC, Rotterdam The Netherlands (sponsor), Hospital Clínic de Barcelona and
      Institut de Recerca de la Sida - Caixa, Barcelona, Spain, Instituut voor Tropische
      Geneeskunde Antwerp, Belgium and Vrije Universiteit Brussel/UZ Brussel, Belgium

      Study population: Chronically HIV-1- infected patients under stable cART with plasma viral
      load (pVL) ≤ 50 copies/ml and stable CD4+ T-cell counts ≥ 450/μl, aged 18 years or above.

      Sample size: after recruitment and screening, 70 patients will be included and randomized to
      one of the study-arms.

      Intervention: One group (n=40) receives the HIVACAT-TriMix (300 microgram TriMix + 900
      microgram HIVACAT) vaccine intranodally on three occasions with a two-week interval. One
      control group (n=15) receives TriMix only (300 microgram TriMix) and one group (n=15)
      receives saline intranodally on three occasions with a two-week interval. Two weeks after the
      last vaccination cART treatment will be interrupted. If plasma virus is detectable, cART will
      be re-initiated twelve weeks after treatment interruption. cART can always be re-initiated
      for medical reasons, as judged by the clinical investigator.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis did not show sufficient immunogenicity of IMP compared to placebo
  </why_stopped>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Actual">February 12, 2018</completion_date>
  <primary_completion_date type="Actual">February 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>week 6</time_frame>
    <description>Grade 3 or above local adverse event (pain, cutaneous reactions including induration).
Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia).
Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively.
Any event attributable to vaccination leading to discontinuation of the immunisation regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity as Measured by Elispot</measure>
    <time_frame>week 6 and week 18</time_frame>
    <description>Change from baseline immunogenicity as measured by ELISPOT at week 6 and 18, i.e. two weeks and 14 weeks after the last immunization compared to both control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as Measured by Intracellular Cytokine Staining (ICS)</measure>
    <time_frame>week 10, 18 and 30</time_frame>
    <description>HIV-specific CD4+ and CD8+ T cell responses after immunization by the number of poly-functional T cells as determined by intracellular cytokine staining, (ICS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Viral Rebound</measure>
    <time_frame>week 6-18</time_frame>
    <description>time until viral rebound (defined as two consecutive measurements of plasma viral load &gt; 1000 copies/mL separated by at least 15 days) after discontinuation at week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Viral Load</measure>
    <time_frame>week 6-18</time_frame>
    <description>difference in log10 copies/ml plasma viral load in vivo after analytical treatment interruption (ATI, week 6-restart ART), compared to placebo WFI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Cure</measure>
    <time_frame>week 18</time_frame>
    <description>proportion of patients with viral load below detectable level of 50 copies/mL in plasma after ATI, week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Immune Response Against Vaccine</measure>
    <time_frame>from baseline to week 6</time_frame>
    <description>Change in frequency of at least 0.7log10 HIV-specific T-cell responses between baseline and week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 T Cell Mediated Viral Suppression</measure>
    <time_frame>week 4</time_frame>
    <description>The capacity of CD8 T cells to suppress virus production in HIV infected autologous CD4 T cells, after vaccination. For this purpose PBMC are isolated and separated in CD8 and CD4 T cells. CD4 cells are infected with HIV. Thereafter CD4 cells are co-cultured with pre-stimulated CD8 cells and the capacity to suppress virus production at different effector to target (E:T) ratios is measured, by the change of p24 Gag production. Pannus et al AIDS 2019, PMID: 30702513</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proviral DNA Reservoir</measure>
    <time_frame>day 0-90 (week 4, week 4 + 1 day and week 5 and week 6) and day 90-130 (week 18) and day &gt;130 (week 30)</time_frame>
    <description>effect on reservoir as measured by changes in the proviral DNA copy numbers per million cells during and after immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Immune Escape</measure>
    <time_frame>week 18</time_frame>
    <description>viral immune escape: change in % mutated epitopes from pre-cART to post-ATI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics</measure>
    <time_frame>week 6 and 18</time_frame>
    <description>host protein mRNA expression profiles in whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated RNA Viral Reservoir</measure>
    <time_frame>day 0-30 (week 4, week 4 + 1 day and week 5) and day 30-80 (week 6), 80-150 days (week 18) and &gt;150 days (week 30)</time_frame>
    <description>effect on reservoir as measured by changes in the intracellular viral RNA copy numbers per million cells during and after immunization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>iHIVARNA-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TriMix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water for injection 3 vaccinations, two weeks interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>iHIVARNA-01</intervention_name>
    <description>Therapeutic vaccination, followed by treatment interruption</description>
    <arm_group_label>iHIVARNA-01</arm_group_label>
    <other_name>HIVACAT</other_name>
    <other_name>TriMix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TriMix</intervention_name>
    <description>Therapeutic vaccination, followed by treatment interruption</description>
    <arm_group_label>TriMix</arm_group_label>
    <arm_group_label>iHIVARNA-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Therapeutic vaccination, followed by treatment interruption</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years of age;

          2. Voluntarily signed informed consent;

          3. Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable
             plasma HIV-1 RNA before initiation of therapy);

          4. On stable treatment with cART regimen (antiretroviral therapy consisting of at least
             three registered antiretroviral agents) for at least 3 years;

          5. Nadir CD4+ ≥ 350 cells/μl (up to 2 occasional determinations ≤ 350 cells/μl are
             allowed);

          6. Current CD4+ cell count ≥ 450 cells/μl;

          7. HIV-RNA below 50 copies/mL in the last 6 months prior to randomization, during at
             least two measurements (occasional so called 'blips' ≤ 500 copies/mL are permitted);

          8. If sexually active, willing to use a reliable method of reducing the risk of
             transmission to their sexual partners during treatment interruption (including PrEP).

               1. For heterosexually active female, using an effective method of contraception with
                  partner (combined oral contraceptive pill; injectable or implanted contraceptive;
                  IUD/IUS; consistent record with condoms; physiological or anatomical sterility
                  (in self or partner) from 14 days prior to the first vaccination until 4 months
                  after the last vaccination.

        For heterosexually active male, using an effective method of contraception with their
        partner from the first day of vaccination until 4 months after the last vaccination. -

        Exclusion Criteria:

          1. Treatment with non-cART regimen prior to cART regimen;

          2. Previous failure to antiretroviral and/or mutations conferring genotypic resistance to
             antiretroviral therapy;

          3. Non-subtype B HIV infection;

          4. Active Hepatitis B virus and/or Hepatitis C virus co-infection;

          5. History of a CDC class C event (see appendix A);

          6. Pregnant female (screened with a positive pregnancy test), lactating or intending to
             become pregnant during the study;

          7. Active malignancy ≤ 30 days (extended period on the clinical assessment of the
             investigator) prior to screening;

          8. Active infection with fever (38°C or above) ≤ 10 days of screening and/or first
             vaccination;

          9. Therapy with immunomodulatory agents (e.g. systemic corticosteroids), including
             cytokines (e.g. IL-2), immunoglobulins and/or cytostatic chemotherapy ≤ 90 days prior
             to screening. This does not include seasonal influenza, hepatitis B and/or other
             travel related vaccines;

         10. Congenital, acquired or induced coagulation disorders, such as thrombocytopenia
             (thrombocytes &lt; 150x109/L) and/or current use of anti-coagulant medication (e.g.
             coumarins, inhibitors of Xa); Usage of NSAIDs (including acetylsalicylic acid) is
             allowed, however it is advised to interrupt therapy 10 days ahead of vaccination;

         11. Usage of any investigational drug ≤ 90 days prior to study entry;

         12. An employee of the investigator or study site, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study site, or is a
             family member of an employee or the investigator Any other condition, which, in the
             opinion of the investigator, may interfere with the evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob A Gruters, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Tropical Medicine</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02413645</url>
    <description>Description phase 1 clinical trial with iHIVARNA-01</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <results_first_submitted>October 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2019</results_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Rob Gruters</investigator_full_name>
    <investigator_title>Workgroup leader</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>mRNA</keyword>
  <keyword>Lentivirus infection</keyword>
  <keyword>Virus disease</keyword>
  <keyword>Sexually transmitted disease</keyword>
  <keyword>Immunodeficiency syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02888756/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>iHIVARNA-01</title>
          <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="P2">
          <title>TriMix</title>
          <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vaccination Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Analytical Treatment Interruption</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>iHIVARNA-01</title>
          <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="B2">
          <title>TriMix</title>
          <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 T cell counts</title>
          <units>cells/microliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="793" lower_limit="689" upper_limit="1041"/>
                    <measurement group_id="B2" value="708" lower_limit="592" upper_limit="961"/>
                    <measurement group_id="B3" value="742" lower_limit="679" upper_limit="918"/>
                    <measurement group_id="B4" value="769" lower_limit="664" upper_limit="974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</title>
        <description>Grade 3 or above local adverse event (pain, cutaneous reactions including induration).
Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia).
Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively.
Any event attributable to vaccination leading to discontinuation of the immunisation regimen.</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</title>
          <description>Grade 3 or above local adverse event (pain, cutaneous reactions including induration).
Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia).
Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively.
Any event attributable to vaccination leading to discontinuation of the immunisation regimen.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity as Measured by Elispot</title>
        <description>Change from baseline immunogenicity as measured by ELISPOT at week 6 and 18, i.e. two weeks and 14 weeks after the last immunization compared to both control groups</description>
        <time_frame>week 6 and week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity as Measured by Elispot</title>
          <description>Change from baseline immunogenicity as measured by ELISPOT at week 6 and 18, i.e. two weeks and 14 weeks after the last immunization compared to both control groups</description>
          <units>delta log difference spot forming units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.35" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.18" lower_limit="-0.17" upper_limit="0.52"/>
                    <measurement group_id="O3" value="0.01" lower_limit="-0.57" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.57" upper_limit="0.42"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.61" upper_limit="0.36"/>
                    <measurement group_id="O3" value="0.45" lower_limit="-0.52" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyzed for week 6, to provide statistical information for decision on execution of intracellular cytokine staining (ICS).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity as Measured by Intracellular Cytokine Staining (ICS)</title>
        <description>HIV-specific CD4+ and CD8+ T cell responses after immunization by the number of poly-functional T cells as determined by intracellular cytokine staining, (ICS).</description>
        <time_frame>week 10, 18 and 30</time_frame>
        <population>The data were not collected. In the protocol it was pre-specified, that ICS would not be done if Elispot results did not show immunogenicity of the study product. This analysis was not performed, because the results from the Elispot assay at the same time points showed no increase in the number of spot-forming units, also see primary outcome two.</population>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity as Measured by Intracellular Cytokine Staining (ICS)</title>
          <description>HIV-specific CD4+ and CD8+ T cell responses after immunization by the number of poly-functional T cells as determined by intracellular cytokine staining, (ICS).</description>
          <population>The data were not collected. In the protocol it was pre-specified, that ICS would not be done if Elispot results did not show immunogenicity of the study product. This analysis was not performed, because the results from the Elispot assay at the same time points showed no increase in the number of spot-forming units, also see primary outcome two.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Viral Rebound</title>
        <description>time until viral rebound (defined as two consecutive measurements of plasma viral load &gt; 1000 copies/mL separated by at least 15 days) after discontinuation at week 6.</description>
        <time_frame>week 6-18</time_frame>
        <population>One participant from the the iHIVARNA-01 group did not interrupt ART and therefor could not be analysed for time to viral rebound. Therefore the number in this group is 15 in stead of 16 at start of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Viral Rebound</title>
          <description>time until viral rebound (defined as two consecutive measurements of plasma viral load &gt; 1000 copies/mL separated by at least 15 days) after discontinuation at week 6.</description>
          <population>One participant from the the iHIVARNA-01 group did not interrupt ART and therefor could not be analysed for time to viral rebound. Therefore the number in this group is 15 in stead of 16 at start of the trial.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="33" upper_limit="57"/>
                    <measurement group_id="O2" value="55.5" lower_limit="43" upper_limit="77"/>
                    <measurement group_id="O3" value="58" lower_limit="36" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Viral Load</title>
        <description>difference in log10 copies/ml plasma viral load in vivo after analytical treatment interruption (ATI, week 6-restart ART), compared to placebo WFI</description>
        <time_frame>week 6-18</time_frame>
        <population>One participant from the the iHIVARNA-01 group did not interrupt ART and therefor could not be analysed for time to viral rebound. Therefore the number in this group is 15 in stead of 16 at start of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Viral Load</title>
          <description>difference in log10 copies/ml plasma viral load in vivo after analytical treatment interruption (ATI, week 6-restart ART), compared to placebo WFI</description>
          <population>One participant from the the iHIVARNA-01 group did not interrupt ART and therefor could not be analysed for time to viral rebound. Therefore the number in this group is 15 in stead of 16 at start of the trial.</population>
          <units>log10 copies/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-1.10" upper_limit="0.77"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-1.18" upper_limit="0.90"/>
                    <measurement group_id="O3" value="1.26" lower_limit="0.21" upper_limit="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Cure</title>
        <description>proportion of patients with viral load below detectable level of 50 copies/mL in plasma after ATI, week 18</description>
        <time_frame>week 18</time_frame>
        <population>One participant from the the iHIVARNA-01 group did not interrupt ART and therefor could not be analysed for time to viral rebound. Therefore the number in this group is 15 in stead of 16 at start of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Cure</title>
          <description>proportion of patients with viral load below detectable level of 50 copies/mL in plasma after ATI, week 18</description>
          <population>One participant from the the iHIVARNA-01 group did not interrupt ART and therefor could not be analysed for time to viral rebound. Therefore the number in this group is 15 in stead of 16 at start of the trial.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Immune Response Against Vaccine</title>
        <description>Change in frequency of at least 0.7log10 HIV-specific T-cell responses between baseline and week 6</description>
        <time_frame>from baseline to week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Immune Response Against Vaccine</title>
          <description>Change in frequency of at least 0.7log10 HIV-specific T-cell responses between baseline and week 6</description>
          <units>delta log spot forming units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.56" upper_limit="0.57"/>
                    <measurement group_id="O2" value="0.17" lower_limit="-0.47" upper_limit="0.81"/>
                    <measurement group_id="O3" value="2.65" lower_limit="1.94" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8 T Cell Mediated Viral Suppression</title>
        <description>The capacity of CD8 T cells to suppress virus production in HIV infected autologous CD4 T cells, after vaccination. For this purpose PBMC are isolated and separated in CD8 and CD4 T cells. CD4 cells are infected with HIV. Thereafter CD4 cells are co-cultured with pre-stimulated CD8 cells and the capacity to suppress virus production at different effector to target (E:T) ratios is measured, by the change of p24 Gag production. Pannus et al AIDS 2019, PMID: 30702513</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>CD8 T Cell Mediated Viral Suppression</title>
          <description>The capacity of CD8 T cells to suppress virus production in HIV infected autologous CD4 T cells, after vaccination. For this purpose PBMC are isolated and separated in CD8 and CD4 T cells. CD4 cells are infected with HIV. Thereafter CD4 cells are co-cultured with pre-stimulated CD8 cells and the capacity to suppress virus production at different effector to target (E:T) ratios is measured, by the change of p24 Gag production. Pannus et al AIDS 2019, PMID: 30702513</description>
          <units>log(pg/ml)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>stimulated (E:T) 2:1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-0.69" upper_limit="0.99"/>
                    <measurement group_id="O2" value="0.22" lower_limit="-0.73" upper_limit="1.16"/>
                    <measurement group_id="O3" value="0.18" lower_limit="-0.48" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stimulated (E:T) 0.1:1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-1.26" upper_limit="-0.05"/>
                    <measurement group_id="O2" value="-1.32" lower_limit="-2.00" upper_limit="-0.65"/>
                    <measurement group_id="O3" value="0.41" lower_limit="-0.08" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proviral DNA Reservoir</title>
        <description>effect on reservoir as measured by changes in the proviral DNA copy numbers per million cells during and after immunization</description>
        <time_frame>day 0-90 (week 4, week 4 + 1 day and week 5 and week 6) and day 90-130 (week 18) and day &gt;130 (week 30)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Proviral DNA Reservoir</title>
          <description>effect on reservoir as measured by changes in the proviral DNA copy numbers per million cells during and after immunization</description>
          <units>delta log copies DNA /10E6 cel</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>proviral DNA 0-90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" lower_limit="-0.007" upper_limit="0.003"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.007" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0.007" lower_limit="0.003" upper_limit="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>proviral DNA 90-130 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" lower_limit="-0.010" upper_limit="0.019"/>
                    <measurement group_id="O2" value="0.004" lower_limit="-0.013" upper_limit="0.020"/>
                    <measurement group_id="O3" value="-0.003" lower_limit="-0.015" upper_limit="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>proviral DNA &gt;130 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" lower_limit="-0.007" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.002" lower_limit="-0.010" upper_limit="0.006"/>
                    <measurement group_id="O3" value="-0.003" lower_limit="-0.007" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Immune Escape</title>
        <description>viral immune escape: change in % mutated epitopes from pre-cART to post-ATI</description>
        <time_frame>week 18</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Immune Escape</title>
          <description>viral immune escape: change in % mutated epitopes from pre-cART to post-ATI</description>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transcriptomics</title>
        <description>host protein mRNA expression profiles in whole blood</description>
        <time_frame>week 6 and 18</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Transcriptomics</title>
          <description>host protein mRNA expression profiles in whole blood</description>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-associated RNA Viral Reservoir</title>
        <description>effect on reservoir as measured by changes in the intracellular viral RNA copy numbers per million cells during and after immunization</description>
        <time_frame>day 0-30 (week 4, week 4 + 1 day and week 5) and day 30-80 (week 6), 80-150 days (week 18) and &gt;150 days (week 30)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iHIVARNA-01</title>
            <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O2">
            <title>TriMix</title>
            <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Cell-associated RNA Viral Reservoir</title>
          <description>effect on reservoir as measured by changes in the intracellular viral RNA copy numbers per million cells during and after immunization</description>
          <units>delta log copies RNA/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>caRNA 0-30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" lower_limit="-0.009" upper_limit="0.007"/>
                    <measurement group_id="O2" value="-0.002" lower_limit="-0.012" upper_limit="0.008"/>
                    <measurement group_id="O3" value="-0.004" lower_limit="-0.011" upper_limit="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>caRNA 30-80 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" lower_limit="-0.015" upper_limit="0.003"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.014" upper_limit="0.010"/>
                    <measurement group_id="O3" value="0.032" lower_limit="0.024" upper_limit="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>caRNA 80-150 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="-0.008" upper_limit="0.012"/>
                    <measurement group_id="O2" value="0.003" lower_limit="-0.008" upper_limit="0.015"/>
                    <measurement group_id="O3" value="-0.016" lower_limit="-0.024" upper_limit="-0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>caRNA &gt;150 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="-0.008" upper_limit="0.011"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.012" upper_limit="0.010"/>
                    <measurement group_id="O3" value="-0.004" lower_limit="-0.011" upper_limit="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>iHIVARNA-01</title>
          <description>Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
iHIVARNA-01: Therapeutic vaccination, followed by treatment interruption
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="E2">
          <title>TriMix</title>
          <description>Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
TriMix: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Water for injection 3 vaccinations, two weeks interval
Placebo: Therapeutic vaccination, followed by treatment interruption</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Entercolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>influenza-like illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site puritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eyelid infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Furunkel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastro enteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine-phospho kinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Althragia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscles spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Burn-out syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Mental disoreder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erythemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotensions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited number of subjects for statistical analysis due to early termination. There was an error in the study product, see https://insights.ovid.com/pubmed?pmid=31490219</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr R.A. Gruters</name_or_title>
      <organization>Erasmus MC</organization>
      <phone>+31 10 7032100</phone>
      <email>r.gruters@erasmusmc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

